ZSAN - Zosano Pharma Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.9003
+0.0470 (+5.51%)
At close: 4:00PM EDT

0.9050 0.00 (0.52%)
Pre-Market: 6:04AM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.8533
Open0.8800
Bid0.9050 x 4000
Ask0.0000 x 1200
Day's Range0.8675 - 0.9090
52 Week Range0.4050 - 3.5400
Volume2,206,978
Avg. Volume2,918,448
Market Cap48.942M
Beta (5Y Monthly)2.62
PE Ratio (TTM)N/A
EPS (TTM)-1.6410
Earnings DateAug 12, 2020 - Aug 17, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Zosano Pharma Initiates Phase 2/3 Clinical Study in Cluster Headache

    Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that the company has begun enrolling cluster headache patients in the ATAC clinical trial. This Phase 2/3 study will evaluate the efficacy of C213 for the acute treatment of cluster headache. C213 is the company’s investigational proprietary formulation of zolmitriptan delivered utilizing its proprietary ADAM patch technology, which consists of titanium micro-projections coated with drug and is the same formulation as QtryptaTM, for the acute treatment of migraine.

  • GlobeNewswire

    Zosano Pharma to Present at the Cantor Global Healthcare Conference

    FREMONT, Calif., Sept. 26, 2019 -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief.

  • GlobeNewswire

    Zosano Pharma Announces the Presentation of Multiple Positive Datasets from the Qtrypta™ Long-Term Safety Study at the Congress of the International Headache Society

    Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced an oral presentation and two poster presentations of positive data from a one-year long-term safety study of Qtrypta™ for the acute treatment of migraine were presented at the 19th Congress of the International Headache Society (IHC) in Dublin, Ireland. The Qtrypta long-term safety study was an open-label trial evaluating the safety of a 3.8 mg dose of intracutaneous zolmitriptan in adults with migraine who had historically experienced at least 2 migraine attacks per month.

  • GlobeNewswire

    Zosano Pharma Announces Upcoming Oral and Poster Presentations at the Congress of the International Headache Society

    Oral presentation of the safety and efficacy of QtryptaTM in a long-term safety study for the acute treatment of migraine.Poster on the results of patients’ freedom from pain.

  • GlobeNewswire

    Zosano Pharma Announces Keynote Speech at the Pharmaceutics & Advanced Drug Delivery Systems Conference

    Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that Hayley Lewis, senior vice president of operations at Zosano Pharma, will be presenting a keynote speech entitled, “A Novel Intracutaneous Microneedle Delivery System for the Acute Treatment of Migraine” at the Pharmaceutics & Advanced Drug Delivery Systems Conference in Paris on July 5, 2019 at 09:15 am CET. Ms. Lewis’ presentation will review Zosano’s novel and proprietary technology platform, the chemistry, manufacturing, and controls of the company’s lead asset, Qtrypta.